Ubs Group Ag Arrowhead Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 450,921 shares of ARWR stock, worth $11.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

450,921

Previous 508,586 11.34%

Holding current value

$11.3 Million

Previous $15.6 Million 17.13%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$27.21 - $39.48 $1.57 Million - $2.28 Million	-57,665 Reduced 11.34%	450,921 $12.9 Million
Q4 2023 Feb 09, 2024	BUY	$21.2 - $31.03 $2.95 Million - $4.31 Million	138,984 Added 37.6%	508,586 $15.6 Million
Q3 2023 Nov 09, 2023	BUY	$26.2 - $36.08 $1.01 Million - $1.39 Million	38,632 Added 11.67%	369,602 $9.93 Million
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $795,760 - $1.31 Million	31,628 Added 10.57%	330,970 $11.8 Million
Q1 2023 May 12, 2023	SELL	$23.68 - $38.51 $198,154 - $322,251	-8,368 Reduced 2.72%	299,342 $7.6 Million

Q4 2022 Feb 08, 2023	BUY	$28.0 - $40.56 $5.72 Million - $8.28 Million	204,164 Added 197.17%	307,710 $12.5 Million
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $365,308 - $595,613	12,329 Added 13.52%	103,546 $3.42 Million
Q2 2022 Aug 10, 2022	SELL	$27.79 - $50.61 $1.89 Million - $3.45 Million	-68,109 Reduced 42.75%	91,217 $3.21 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $170,762 - $301,570	4,310 Added 2.78%	159,326 $7.33 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $1.45 Million - $2.06 Million	25,016 Added 19.24%	155,016 $10.3 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $3.37 Million - $4.91 Million	57,787 Added 80.02%	130,000 $8.12 Million
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $16,904 - $24,567	272 Added 0.38%	72,213 $5.98 Million
Q1 2021 May 12, 2021	BUY	$61.35 - $90.47 $3.7 Million - $5.46 Million	60,386 Added 522.6%	71,941 $4.77 Million
Q4 2020 Feb 11, 2021	SELL	$43.82 - $85.37 $945,767 - $1.84 Million	-21,583 Reduced 65.13%	11,555 $887,000
Q3 2020 Nov 12, 2020	BUY	$33.21 - $51.27 $841,342 - $1.3 Million	25,334 Added 324.63%	33,138 $1.43 Million
Q2 2020 Jul 31, 2020	SELL	$26.12 - $43.27 $110,983 - $183,854	-4,249 Reduced 35.25%	7,804 $337,000
Q1 2020 May 01, 2020	SELL	$20.56 - $63.12 $4.03 Million - $12.4 Million	-196,122 Reduced 94.21%	12,053 $347,000
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $91,061 - $236,260	-3,236 Reduced 1.53%	208,175 $13.2 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $2.55 Million - $3.38 Million	96,985 Added 84.76%	211,411 $5.96 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $1.04 Million - $1.72 Million	59,812 Added 109.52%	114,426 $3.03 Million
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $2.7 Million - $4.53 Million	-224,405 Reduced 80.43%	54,614 $1 Million
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $2.1 Million - $3.85 Million	195,436 Added 233.82%	279,019 $3.47 Million
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $706,202 - $1.02 Million	50,443 Added 152.21%	83,583 $1.6 Million
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $1.08 Million - $2.38 Million	-169,625 Reduced 83.66%	33,140 $451,000
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $670,291 - $1.38 Million	180,186 Added 798.02%	202,765 $1.46 Million
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $33,538 - $48,064	10,681 Added 89.77%	22,579 $83,000
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $10,547 - $27,023	6,241 Added 110.32%	11,898 $51,000
Q2 2017 Aug 14, 2017	BUY	N/A	357 Added 6.74%	5,657 $10,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,300	5,300 $10,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.65B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account